Download PDFPDF

Case report and literature review of Huntington disease with intermediate CAG expansion
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses [].
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses [] and understand that your personal data will be processed in accordance with those terms and our privacy notice [].
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Author Response
    • Stefan D Jevtic, Internal Medicine Resident McMaster University
    • Other Contributors:
      • John Provias, Neuropathologist

    We would like to begin by thanking Dr. Ratna for his interest and thoughtful comments surrounding our paper. As we previously highlighted, there are several case reports in the literature of individuals with fewer than 36 CAG repeats and clinical signs of Huntington Disease (HD). These cases are not definitive and often do not feature autopsy confirmation of diagnosis; however, they present an interesting clinical dilemma for physicians. In our case, there was both convincing evidence for clinical and neuropathological diagnosis that would suggest HD. Alternative diagnoses, including neuroacanthosis, were not consistent with the patient’s history and initial presentation. Specifically, orofacial movements were not prominent in her initial assessment and reflexes were present. Furthermore, there was no significant history of infectious symptoms or likelihood of toxic ingestion to suggest these alternative diagnoses. Family history was limited, and additional genetic testing was not pursued after consulting several expert neurologists, who ultimately supported a clinical diagnosis of HD.

    Unfortunately, due to technical limitations we were unable to obtain staining for huntingtin protein on our tissue samples. Similarly, DNA extraction and additional molecular techniques were unavailable, but we agree that these would have been ideal to further investigate underlying
    mechanisms of disease. The interesting pathology findings of amyloid-beta staining involved the c...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Reply to Case report and literature review of Huntington disease with intermediate CAG expansion
    • Nikhil Ratna, PhD scholar National Institute of Mental Health and Neurosciences

    This case report by Jevtic et al addresses one of the interesting and critical issue sdefining the genetic mutation causing Huntington's disease. Threshold of repeat number causing HD was defined and redefined since 1993 due to the emerging data and the development of novel, precise methods for determining CAG repeats such as those exclude CGG expansions at the C terminal end of CAG tract.

    Despite all these efforts, there are sporadic case reports of HD phenotypes with repeats < 36 (widely accepted threshold for causing HD). Most of these case reports do not exclude HD like syndromes (HDL1/2/3/4, Neuro-acanthocytosis) caused by other mutations. Besides these mutations there could be toxins, infections which could have contributed to the HD phenotype and the occurrence of Intermediate alleles (IAs) in these patients is a chance event. This possibility could be duly considered for the fact that many IAs carried by parent generation of de-novo HD cases do not cause any symptoms. However IAs cannot be given a clean chit in HD pathogenesis until proven by studying CAG distribution in normal population along with HD population with enough statistical power.

    In this case report, firstly authors could have brought more evidence to their proposition by ruling out alternative diagnoses such as Neuro-acanthocytosis which can be clinically distinguished (absence of deep tendon reflexes, more prominent oro-facial movements) even in the absence of genetic mutatio...

    Show More
    Conflict of Interest:
    None declared.